Cancer immunotherapy: challenges and clinical applications

Genetic and phenotypic difference in CD8+T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma

(2018) Xiaochen Wang et al.   JOURNAL OF MEDICAL GENETICS

Exosomes derived from exhausted CD8+ T cells impaired the anticancer function of normal CD8+ T cells

(2018) Xiaochen Wang et al.   JOURNAL OF MEDICAL GENETICS

Applications and advances of CRISPR-Cas9 in cancer immunotherapy

(2018) An-Liang Xia et al.   JOURNAL OF MEDICAL GENETICS

Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target

(2018) Dongming Chen et al.   JOURNAL OF MEDICAL GENETICS

Bacteria-free minicircle DNA system to generate integration-free CAR-T cells

(2018) Chen Cheng et al.   JOURNAL OF MEDICAL GENETICS

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

Global microarray profiling identifiedhsa_circ_0064428as a potential immune-associated prognosis biomarker for hepatocellular carcinoma

(2018) Qiaoyou Weng et al.   JOURNAL OF MEDICAL GENETICS

High response rate to PD-1 blockade in desmoplastic melanomas

(2018) Zeynep Eroglu et al.   NATURE

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Coinhibitory Pathways in Immunotherapy for Cancer

(2016) Susanne H. Baumeister et al.   Annual Review of Immunology

Toxicities of chimeric antigen receptor T cells: recognition and management

(2016) Jennifer N. Brudno et al.   BLOOD

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

(2016) Antoni Ribas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

(2016) Axel Hoos   NATURE REVIEWS DRUG DISCOVERY

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

(2016) Paul T. Nghiem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab

(2015) Zeynep Eroglu et al.   EUROPEAN JOURNAL OF CANCER

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

(2015) A. Ribas   Cancer Discovery

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY